

Press release  
20 February 2018



## **Gyros Protein Technologies and Fleet Bioprocessing partner to offer assay development and transfer services**

*Fleet to provide support to Gyrolab users in developing, transferring and optimizing assays for the platform*

**Uppsala, Sweden, and Hampshire, UK, 20 February 2018:** Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, and Fleet Bioprocessing Ltd. (Fleet), an expert provider of contract immunoassay development services and immunoassay reagent manufacture, announced today that they have signed a Certified Assay Transfer & Development Partner agreement, under which Fleet will provide assay development, transfer and optimization services for Gyrolab® platform users.

Gyrolab platforms offer great advantages over traditional assay formats by streamlining assay workflow to support rapid decision-making in drug development. Historically, accessing the resource internally to transfer assays from existing formats to work with the automated, nanoliter-scale Gyrolab® xP and Gyrolab xPlore™ immunoassay systems, has been challenging. Through this new partnership agreement, Gyrolab users worldwide can now easily access such services, either via Gyros Protein Technologies or by working directly with Fleet.

Fleet is an industry-leading expert in all aspects of immunoassay design, development and validation, with extensive know-how in immunoassay development for biotech, pharma and clinical diagnostic applications. Fleet has successfully executed assay development projects ranging from feasibility assessments to CE-marking studies, and is certified to ISO9001:2015 and ISO13485:2016, demonstrating robust and effective quality standards.

**Mark Vossenaar, VP Sales EMEA, Gyros Protein Technologies, said:** “This partnership was established in response to feedback from our customer base for the need to provide support in developing, transferring and optimizing assays onto the Gyrolab platform. We felt that an independent third-party specialist was best placed to provide this service, and we are confident we have chosen the ideal partner in Fleet Bioprocessing.”

**Alastair Dent, Managing Director, Fleet Bioprocessing, said:** “We are delighted to be working with Gyros Protein Technologies, and we are already seeing great interest in the new service, with our first project well under way and many more in the pipeline.”

**ENDS**

**Notes to editors**



Photo: Gyrolab xP workstation

**For a high resolution image please contact Zyme Communications**

**Media contact:**

Katie Odgaard

Zyme Communications

Tel: +44(0)7787 503 947

Email: [Katie.odgaard@zymecommunications.com](mailto:Katie.odgaard@zymecommunications.com)

**About Gyros Protein Technologies** (For more information please click [here](#))

Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.

**About Fleet Bioprocessing** (For more information please click [here](#))

Fleet Bioprocessing Ltd. offers contract development, validation and manufacturing services for the immunoassay sector. Based on decades of industry experience, Fleet are experts in the development of immunoassays on a wide range of platforms, validation of these assays to verify effective performance and to support regulatory certification, and the development and manufacture of critical assay reagents such as labelled antibody conjugates. Certified to ISO9001:2015 and ISO13485:2016, Fleet has an exemplary audit record over its 18-year history and operates to the highest quality standards to ensure that assay development is executed and documented to meet all regulatory requirements.